Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) received a $8.00 price target from analysts at Maxim Group in a research note issued on Saturday. The firm presently has a “buy” rating on the biotechnology company’s stock. Maxim Group’s price target suggests a potential upside of 61.94% from the company’s current price.

Separately, ValuEngine raised Brainstorm Cell Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday.

Brainstorm Cell Therapeutics (NASDAQ BCLI) traded up 9.05% on Friday, reaching $4.94. The company’s stock had a trading volume of 1,002,873 shares. The stock’s market cap is $92.55 million. The stock has a 50-day moving average of $4.29 and a 200-day moving average of $3.85. Brainstorm Cell Therapeutics has a one year low of $2.06 and a one year high of $5.18.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last posted its quarterly earnings data on Monday, May 15th. The biotechnology company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.20. On average, analysts predict that Brainstorm Cell Therapeutics will post ($0.79) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Brainstorm Cell Therapeutics Inc. (BCLI) Given a $8.00 Price Target by Maxim Group Analysts” was first reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/07/23/brainstorm-cell-therapeutics-inc-bcli-given-a-8-00-price-target-by-maxim-group-analysts.html.

An institutional investor recently raised its position in Brainstorm Cell Therapeutics stock. KCG Holdings Inc. raised its stake in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) by 4.6% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 41,537 shares of the biotechnology company’s stock after buying an additional 1,820 shares during the period. KCG Holdings Inc. owned 0.22% of Brainstorm Cell Therapeutics worth $177,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 8.02% of the company’s stock.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others.

Receive News & Ratings for Brainstorm Cell Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.